Amgen Inc. (NASDAQ:AMGN) Stock Holdings Increased by Evergreen Wealth Management LLC

Evergreen Wealth Management LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,892 shares of the medical research company’s stock after purchasing an additional 84 shares during the period. Evergreen Wealth Management LLC’s holdings in Amgen were worth $1,409,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in AMGN. OFI Invest Asset Management purchased a new stake in Amgen during the third quarter valued at about $26,000. Briaud Financial Planning Inc acquired a new stake in shares of Amgen during the third quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $29,000. Providence Capital Advisors LLC acquired a new position in Amgen in the 3rd quarter worth approximately $30,000. Finally, Planned Solutions Inc. purchased a new position in Amgen during the 4th quarter worth approximately $30,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $230.00 to $300.00 in a report on Friday. Morgan Stanley lifted their target price on Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday. Royal Bank of Canada reduced their price target on shares of Amgen from $332.00 to $328.00 and set an “outperform” rating for the company in a research report on Friday. UBS Group raised their price target on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $305.05.

Amgen Stock Performance

Shares of Amgen stock traded up $32.90 on Friday, reaching $311.29. The stock had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The business’s 50-day moving average price is $274.95 and its two-hundred day moving average price is $281.46. The stock has a market cap of $166.97 billion, a P/E ratio of 44.47, a price-to-earnings-growth ratio of 3.01 and a beta of 0.60. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 145.62%. The business’s revenue was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.98 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.